Clinical Pocket Guide: Diagnostic Testing for HER2, HER3, and TROP2 and Treatment Implications in Breast, GI, and Lung Cancers

Download this PDF summarizing key points in HER2, HER3, and TROP2 testing and targeted therapy for patients with breast, GI, and lung cancers.
Mark D. Pegram, MD
Program Director
Michael F. Press, MD, PhD
Format: Adobe Acrobat (.pdf)
File Size: 157 KB
Released: July 30, 2020

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
Daiichi Sankyo, Inc.

Related Content

From Clinical Care Options (CCO), download a PDF featuring expert discussion on using immunotherapy for patients with advanced HCC

Lipika Goyal, MD Amit G. Singal, MD, MS Released: January 22, 2021

From Clinical Care Options (CCO), on-demand Webcast with Lee Schwartzberg, MD, FACP, and Ruth O’Regan, MD, on optimal treatment of breast cancer brain metastases

Ruth O'Regan, MD Lee Schwartzberg, MD, FACP Physicians: maximum of 1.25 AMA PRA Category 1 Credits ABIM MOC: maximum of 1.25 Medical Knowledge MOC point(s) Released: January 22, 2021 Expired: January 21, 2022

Expert video from live CCO Webinar on using immune checkpoint inhibitors and antibody–drug conjugates for early-stage through metastatic TNBC

Heather McArthur, MD, MPH
Program Director
Kevin Kalinsky, MD, MS Rita Nanda, MD
Physicians: maximum of 1.25 AMA PRA Category 1 Credits ABIM MOC: maximum of 1.25 Medical Knowledge MOC point(s) Released: January 22, 2021 Expired: January 21, 2022

From Clinical Care Options (CCO), download a PDF featuring expert answers to clinician questions on using immunotherapy for patients with advanced HCC

Lipika Goyal, MD Amit G. Singal, MD, MS Released: January 21, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue